Cargando…

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin

Expression of the TUSC2/FUS1 tumor suppressor gene in TUSC2 deficient EGFR wildtype lung cancer cells increased sensitivity to erlotinib. Microarray mRNA expression analysis of TUSC2 inducible lung cancer cells treated with erlotinib uncovered defects in the response to oxidative stress suggesting t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiaobo, Cao, Majidi, Mourad, Feng, Meng, Shao, Ruping, Wang, Jing, Zhao, Yang, Baladandayuthapani, Veerabhadran, Song, Juhee, Fang, Bingliang, Ji, Lin, Mehran, Reza, Roth, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109231/ https://www.ncbi.nlm.nih.gov/pubmed/27845352 http://dx.doi.org/10.1038/srep35741

Ejemplares similares

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy
por: Dai, Bingbing, et al.
Publicado: (2015)

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
por: Meng, Jieru, et al.
Publicado: (2013)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans
por: Lu, Charles, et al.
Publicado: (2012)

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
por: Cao, Xiaobo, et al.
Publicado: (2017)

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
por: Li, Hongyu, et al.
Publicado: (2015)

Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
por: Ivanova, Alla V, et al.
Publicado: (2009)

Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics
por: Gentile, Emanuela, et al.
Publicado: (2017)

Tusc2/Fus1 regulates osteoclast differentiation through NF-κB and NFATc1
por: Kim, Inyoung, et al.
Publicado: (2017)

Auranofin: Repurposing an Old Drug for a Golden New Age
por: Roder, Christine, et al.
Publicado: (2015)

Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci
por: AbdelKhalek, Ahmed, et al.
Publicado: (2018)

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
por: Wang, Jeffrey, et al.
Publicado: (2019)

Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis
por: Bulman, Christina A., et al.
Publicado: (2015)

Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System
por: May, Holly C., et al.
Publicado: (2018)

Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis
por: Uzhachenko, Roman, et al.
Publicado: (2017)

Mitochondrial Fus1/Tusc2 and cellular Ca2(+) homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications
por: Uzhachenko, Roman, et al.
Publicado: (2022)

Repurposing of auranofin and honokiol as antifungals against Scedosporium species and the related fungus Lomentospora prolificans
por: Yaakoub, Hajar, et al.
Publicado: (2021)

Pharmacological Modulation of Energy and Metabolic Pathways Protects Hearing in the Fus1/Tusc2 Knockout Model of Mitochondrial Dysfunction and Oxidative Stress
por: Tan, Winston J. T., et al.
Publicado: (2023)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC
por: Jeon, Young-Jun, et al.
Publicado: (2018)

The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs
por: Rutnam, Zina Jeyapalan, et al.
Publicado: (2014)

Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib
por: Amri, Jamal, et al.
Publicado: (2019)

Repurposing Auranofin, an Anti-Rheumatic Gold Compound, to Treat Acne Vulgaris by Targeting the NLRP3 Inflammasome
por: Yang, Gabsik, et al.
Publicado: (2020)

Repurposing non-antifungal drugs auranofin and pentamidine in combination as fungistatic antifungal agents against C. albicans
por: Lin, Jiaying, et al.
Publicado: (2022)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Cyclic Voltammetry of Auranofin
por: Mohamed, Ahmed A., et al.
Publicado: (1999)

Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs
por: Jin, Mengmeng, et al.
Publicado: (2021)

Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway
por: Thangamani, Shankar, et al.
Publicado: (2017)

Bayesian Disease Classification Using Copy Number Data
por: Guha, Subharup, et al.
Publicado: (2014)

BaySyn: Bayesian Evidence Synthesis for Multi-system Multiomic Integration
por: Bhattacharyya, Rupam, et al.
Publicado: (2023)

Integrative Bayesian Network Analysis of Genomic Data
por: Ni, Yang, et al.
Publicado: (2014)

Bayesian Covariate-Dependent Gaussian Graphical Models with Varying Structure
por: Ni, Yang, et al.
Publicado: (2022)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

TUSC2P suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and correlates with disease prognosis
por: Liu, Fengqiong, et al.
Publicado: (2018)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
por: Pirola, Carlos J., et al.
Publicado: (2022)

Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic
por: Weiss, Glen J., et al.
Publicado: (2014)

Transcriptional Profiling of a Patient-Matched Cohort of Glioblastoma (IDH-Wildtype) for Therapeutic Target and Repurposing Drug Identification
por: Roddy, Aideen C., et al.
Publicado: (2023)

Classification, Predictive Modelling, and Statistical Analysis of Cancer Data (A)
por: Jiang, Hongmei, et al.
Publicado: (2014)

Prognostic Gene Signature Identification Using Causal Structure Learning: Applications in Kidney Cancer
por: Ha, Min Jin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n3iaop00onnm6s0cspubeafp5d